Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 2/20 | 0.55 |
| ▸ | F10 | P00742 | 2/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | TOP2A | P11388 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.47 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12112474 | 0.93 | HTR4 (0.62) | HTR4F10BRD4SUV39H2ROCK2 | |
| SCHEMBL13846080 | 0.80 | HTR4 (0.67) | HTR4F10BRD4SUV39H2ROCK2 | |
| Hydrochloric Acid SCHEMBL11714021 | 0.76 | TDP1 (0.74) | HTR4BRD4ROCK2SMYD3TDP1 | |
| Trifluoroacetic Acid SCHEMBL16208877 | 0.75 | HTR4 (0.46) | HTR4BRD4TDP1 | |
| SCHEMBL1313080 | 0.75 | KDM4E (0.66) | HTR4F10SUV39H2KCNH2CACNA1I | |
| SCHEMBL6066542 | 0.74 | F10 (0.85) | F10 | |
| SCHEMBL13575608 | 0.74 | HTR4 (0.61) | HTR4F10BRD4SUV39H2ROCK2 | |
| SCHEMBL13846100 | 0.74 | HTR4 (0.61) | HTR4F10BRD4SUV39H2ROCK2 | |
| SCHEMBL13846092 | 0.74 | HTR4 (0.61) | HTR4F10BRD4SUV39H2ROCK2 | |
| Hydrochloric Acid SCHEMBL6066473 | 0.74 | F10 (0.83) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2375899-B1 | PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF IN THE TREATMENT OF DIABETES | ARRAY BIOPHARMA INC (US) | 2015-02-25 | — | — | EP | disclosed |
| US-8809538-B2 | Piperidine-containing compounds and use thereof | ARRAY BIOPHARMA INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20110275608-A1 | PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-11-10 | — | — | US | disclosed |
| EP-2375899-A1 | PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF | Array Biopharma, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010080864-A1 | PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275608-A1 | PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF | NOS1, NOS2, ASS1 | HTR4 2748/4885F10 4375/4885BRD4 2695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.